Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients.

OBJECTIVE

Cell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resistant prostate cancer (mCRPC) patients.

METHODS

Seventy-two mCRPC patients who underwent abiraterone plus prednisone therapy were included in this retrospective study, followed by the serum CDC42 level determination at baseline and month 2 (M2). Additionally, serum CDC42 was detected in thirty age-matched healthy controls (HCs).

RESULTS

The CDC42 level was higher in mCRPC patients versus HCs [median (interquartile range): 1012.5 (655.8-1671.3) versus 606.0 (392.0-1007.0) pg/mL] (P < 0.001). Meanwhile, the CDC42 level was associated with lymph node metastasis (P = 0.041) and visceral metastasis (P = 0.005), but not other clinical characteristics (P > 0.050) in mCRPC patients. Additionally, the CDC42 level was decreased after 2-month treatment (P < 0.001). Inspiringly, shorter radiographic progression-free survival (rPFS) was observed in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at baseline (P = 0.035). Furthermore, shorter rPFS (P = 0.002) and overall survival (P = 0.043) were discovered in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at M2. More importantly, CDC42 at M2 (> 1000 vs. ≤ 1000 pg/mL) was independently associated with shorter rPFS in mCRPC patients (P = 0.035, hazard ratio = 2.203).

CONCLUSION

The serum CDC42 level associates with LNM, visceral metastasis, and worse prognosis in mCRPC patients underwent abiraterone plus prednisone therapy. However, future prospective, large-scale, and controlled studies are needed for validation.